Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod for Stiff Person Syndrome
NCT06528392Phase 2Not yet recruiting
- Sponsor
- University of South Florida
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Fragments, Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa + hyaluronidase-qvfc in stiff person syndrome (SPS), sponsored by University of South Florida. Primary endpoints: Distribution of Stiffness Index at 13 weeks and Heightened Sensitivity Score at 13 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
stiff person syndrome (SPS)
Beyond the preview
Go deeper on NCT06528392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528392.